Similar articles

• Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.

  Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO. Alloway RR, et al. Transplant Proc. 1996 Apr;28(2):995-7. Transplant Proc. 1996. PMID: 8623494 Clinical Trial. No abstract available.
• Immunosuppressive effects of FK 506 on rat renal allograft survival, in comparison with cyclosporine.

  Jiang H, Fujitsu T, Sakuma S, Ogawa T, Tamura K, Fujii Y, Akiyama Y, Izumi S, Takahara S, Ishibashi M, et al. Jiang H, et al. Transplant Proc. 1995 Feb;27(1):367-9. Transplant Proc. 1995. PMID: 7533413 No abstract available.
• A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar?

  Morozumi K, Sugito K, Oda A, Takeuchi O, Fukuda M, Usami T, Oikawa T, Fujinami T, Koyama K, Takeda A, Yoshida A, Haba T, Tominaga Y, Uchida K, Yokoyama I, Takagi H. Morozumi K, et al. Transplant Proc. 1996 Apr;28(2):1076-8. Transplant Proc. 1996. PMID: 8623232 No abstract available.
• Cyclosporin-associated thrombotic microangiopathy: successful retreatment with cyclosporin.

  Bolin P Jr, Jennette JC, Mandel SR. Bolin P Jr, et al. Ren Fail. 1991;13(4):275-8. doi: 10.3109/08860229109022164. Ren Fail. 1991. PMID: 1780496 Review.
• Management of nephrotoxic drugs.

  Alsina J. Alsina J. Transplant Proc. 1999 Feb-Mar;31(1-2):1117-9. doi: 10.1016/s0041-1345(98)01927-7. Transplant Proc. 1999. PMID: 10083499 Review. No abstract available.